Advanced search
Publication Cover
Leukemia & Lymphoma Volume 63, 2022 - Issue 12
Submit an article Journal homepage
2,270
Views
1
CrossRef citations to date
0
Altmetric
Letters to the Editor

Evaluation of pulmonary toxicities in lymphoma patients receiving brentuximab vedotin

Tiffany Guana Department of Pharmaceutical Services, University of California, San Francisco Medical Center, San Francisco, CA, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-4332-0891
ORCID Icon,
Mimi Loa Department of Pharmaceutical Services, University of California, San Francisco Medical Center, San Francisco, CA, USA
,
Rebecca Younga Department of Pharmaceutical Services, University of California, San Francisco Medical Center, San Francisco, CA, USA
,
Weiyun Aib Department of Medicine, Division of Hematology/BMT, University of California, San Francisco, San Francisco, CA, USA
,
Fouad Boulbolc Community Cancer Institute, Community Medical Center, Clovis, CA, USA
,
Hanson Mouanoutouad Department of Medicine, University of California, San Francisco, Fresno Campus, Fresno, CA, USA
,
Raymond Chue School of Pharmacy, University of California, San Francisco, San Francisco, CA, USA
,
Charalambos Andreadisb Department of Medicine, Division of Hematology/BMT, University of California, San Francisco, San Francisco, CA, USA
,
Lawrence Kaplanb Department of Medicine, Division of Hematology/BMT, University of California, San Francisco, San Francisco, CA, USA
,
Haifaa Abdulhaqd Department of Medicine, University of California, San Francisco, Fresno Campus, Fresno, CA, USA
&
Bita Fakhrib Department of Medicine, Division of Hematology/BMT, University of California, San Francisco, San Francisco, CA, USA
 show all
Pages 3008-3011 | Received 03 Jun 2022, Accepted 01 Jul 2022, Published online: 25 Jul 2022

References

  • Seattle Genetics. ADCETRIS (brentuximab vedotin) [package insert]. U.S. Food and Drug Administration; 2020 [updated 2017 Nov; cited 2020 Dec 12]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125388s094lbl.pdf
  • Straus DJ, Długosz-Danecka M, Connors JM, et al. Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial. Lancet Haematol. 2021;8(6):e410–e421.
  • Advani RH, Moskowitz AJ, Bartlett NL, et al. Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results. Blood. 2021;138(6):427–438.
  • Moskowitz AJ, Herrera AF, Beaven AW. Relapsed and refractory classical Hodgkin lymphoma: keeping pace with novel agents and new options for salvage therapy. Am Soc Clin Oncol Educ Book. 2019;39:477–486.
  • Moskowitz CH, Walewski J, Nademanee A, et al. Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse. Blood. 2018;132(25):2639–2642.
  • Horwitz S, O'Connor OA, Pro B, et al. The ECHELON-2 trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma. Ann Oncol. 2022;33(3):288–298.
  • National Comprehensive Cancer Network Guidelines. Hodgkin’s lymphoma (2.2020); 2020; Plymouth Meeting, PA.
  • National Comprehensive Cancer Network Guidelines. B-cell lymphoma (4.2020); 2020; Plymouth Meeting, PA.
  • Connors JM, Jurczak W, Straus DJ, et al. Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin’s lymphoma. N Engl J Med. 2018;378(4):331–344.
  • Faulk KE, Sopfe JM, Campbell K, et al. Pulmonary toxicity in paediatric patients with relapsed or refractory Hodgkin lymphoma receiving brentuximab vedotin. Br J Haematol. 2018;183(2):251–256.
  • Katta S, Connolly T, et al. Acute drug-induced pneumonitis from brentuximab therapy [conference presentation abstract]. American Thoracic Society 2019 International Conference; 2019 May 19; Dallas, TX.
  • Sabet Y, Ramirez S, Cespedes ER, et al. Severe acute pulmonary toxicity associated with brentuximab in a patient with refractory Hodgkin’s lymphoma. Case Rep Pulmonol. 2016;2016:2359437.
  • Brentuximab vedotin [package insert]. Bothell (WA): Seattle Genetics, Inc.; 2011.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.